Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Trial Details

NCT ID
NCT05910398
Phase
PHASE3
Sponsor
RenJi Hospital
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • pyrotinib
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Histologically confirmed invasive HER2 positive breast cancer;
  • Duration from random time to the last use of trastuzumab or T-DM1 ≤3 years;
  • Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1;
  • Adequate organ functions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →